During the past decade, Retina Group of New England conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 8 clinical trials were completed, i.e. on average, 36.4% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 7 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Group of New England" #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "Kodiak Sciences Inc" with 4 trials sponsored, "Jaeb Center for Health Research" with 2 trials sponsored, "Amgen" with 1 trials sponsored and "Apellis Pharmaceuticals, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Group of New England" #1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator, "National Eye Institute (NEI)" with 2 trials as a collaborator, "Allergan" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "National Institutes of Health (NIH)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Retina Group of New England" are "Diabetic Macular Edema" (6 trials), "Geographic Atrophy" (3 trials), "Macular Edema" (3 trials), "Diabetic Retinopathy" (2 trials) and "Neovascular Age-Related Macular Degeneration" (2 trials). Many other conditions were trialed in "Retina Group of New England" in a lesser frequency.

Most popular intervention types in "Retina Group of New England" are "Drug" (23 trials), "Other" (8 trials), "Procedure" (6 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (10 trials), "Aflibercept" (8 trials), "Faricimab" (6 trials), "KSI-301" (4 trials) and "Intravitreal Ranibizumab 0.5 mg Injection" (2 trials). Other intervention names were less common.

The vast majority of trials in "Retina Group of New England" are 23 trials for "All" genders.

Currently, there are NaN active trials in "Retina Group of New England". undefined are not yet recruiting, 2 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Retina Group of New England, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Group of New England, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".